AU722617B2 - Parenteral paclitaxel in a stable non-toxic formulation - Google Patents

Parenteral paclitaxel in a stable non-toxic formulation Download PDF

Info

Publication number
AU722617B2
AU722617B2 AU36478/97A AU3647897A AU722617B2 AU 722617 B2 AU722617 B2 AU 722617B2 AU 36478/97 A AU36478/97 A AU 36478/97A AU 3647897 A AU3647897 A AU 3647897A AU 722617 B2 AU722617 B2 AU 722617B2
Authority
AU
Australia
Prior art keywords
paclitaxel
dma
pharmaceutical composition
peg
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36478/97A
Other languages
English (en)
Other versions
AU3647897A (en
Inventor
Borje S Andersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24699210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU722617(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU3647897A publication Critical patent/AU3647897A/en
Application granted granted Critical
Publication of AU722617B2 publication Critical patent/AU722617B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU36478/97A 1996-06-28 1997-06-26 Parenteral paclitaxel in a stable non-toxic formulation Ceased AU722617B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/672,594 US5877205A (en) 1996-06-28 1996-06-28 Parenteral paclitaxel in a stable non-toxic formulation
US08/672594 1996-06-28
PCT/US1997/011503 WO1998000128A1 (en) 1996-06-28 1997-06-26 Parenteral paclitaxel in a stable non-toxic formulation

Publications (2)

Publication Number Publication Date
AU3647897A AU3647897A (en) 1998-01-21
AU722617B2 true AU722617B2 (en) 2000-08-10

Family

ID=24699210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36478/97A Ceased AU722617B2 (en) 1996-06-28 1997-06-26 Parenteral paclitaxel in a stable non-toxic formulation

Country Status (9)

Country Link
US (2) US5877205A (enExample)
EP (1) EP0920311A4 (enExample)
JP (1) JP2000515132A (enExample)
CN (1) CN1165300C (enExample)
AU (1) AU722617B2 (enExample)
CA (1) CA2259297C (enExample)
NO (1) NO986165L (enExample)
NZ (1) NZ333737A (enExample)
WO (1) WO1998000128A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
KR100446959B1 (ko) * 1998-04-02 2004-11-03 김종국 파클리탁셀주사제조성물
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
CA2356959C (en) * 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
PL350075A1 (en) * 2000-02-02 2002-11-04 Univ Florida State Res Found Taxane formulations having improved solubility
AU2001258872C1 (en) 2000-05-12 2005-05-26 Samyang Biopharmaceuticals Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
WO2003022248A1 (en) * 2001-09-13 2003-03-20 Korea Institute Of Science And Technology Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2003047508A2 (en) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Paclitaxel solvates
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
US20040213837A1 (en) * 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
US20050129719A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Concentrated emulsion formulation for silatecan
US20050220835A1 (en) * 2004-03-30 2005-10-06 Jayaraman Ramesh B Agent eluting bioimplantable devices and polymer systems for their preparation
CN101023119B (zh) * 2004-09-22 2010-05-05 日本化药株式会社 新型嵌段共聚物，胶束制剂以及含胶束制剂为活性组分的抗癌剂
WO2007014445A1 (en) * 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
KR20080106254A (ko) * 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
CA2652656A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
EP2080779B1 (en) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
US8703878B2 (en) * 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
CN102038636B (zh) * 2009-10-23 2014-08-13 天士力控股集团有限公司 一种含有螯合剂的紫杉烷类药物溶液及其制备方法
CN102038634B (zh) * 2009-10-23 2014-12-10 天士力控股集团有限公司 一种含有助溶剂的紫杉烷类药物溶液及其制备方法
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
TWI472340B (zh) * 2010-11-10 2015-02-11 Tasly Holding Group Co Ltd Taxanes containing solution and a preparation method of the co-solvent
JP5856069B2 (ja) 2010-11-17 2016-02-09 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
JP5711378B2 (ja) 2011-09-11 2015-04-30 日本化薬株式会社 ブロック共重合体の製造方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN109464382B (zh) * 2019-01-08 2020-10-09 四川大学 一种可注射的高载药量的紫杉醇凝胶及其制备方法和应用
CN118434408A (zh) * 2021-10-21 2024-08-02 卡希夫生物科学有限公司 卡非佐米的稳定即用稀释组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5430057A (en) * 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof

Also Published As

Publication number Publication date
AU3647897A (en) 1998-01-21
US5877205A (en) 1999-03-02
WO1998000128A1 (en) 1998-01-08
NZ333737A (en) 2000-02-28
CN1228022A (zh) 1999-09-08
CN1165300C (zh) 2004-09-08
JP2000515132A (ja) 2000-11-14
NO986165L (no) 1999-02-25
EP0920311A4 (en) 2001-10-04
CA2259297C (en) 2003-12-16
NO986165D0 (no) 1998-12-28
EP0920311A1 (en) 1999-06-09
US6107333A (en) 2000-08-22
CA2259297A1 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
US5877205A (en) Parenteral paclitaxel in a stable non-toxic formulation
US5681846A (en) Extended stability formulations for paclitaxel
TW457095B (en) Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
AU774060B2 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
KR890004684B1 (ko) 소수성약제의 전달용 약제학적 조성물
CA2171738C (en) Parenteral busulfan for treatment of malignant disease
AU775158B2 (en) Water-miscible pharmaceutical compositions of paclitaxel
CA2295478A1 (en) Parenteral pimaricin as treatment of systemic infections
WO2007020085A2 (en) Compositions containing taxane derivatives for intravenous injection
CN103974703A (zh) 卡巴他赛制剂及其制备方法
JP2005525310A (ja) タキサンを主剤とした組成物およびその使用法
CN110812335B (zh) 装载疏水药物的丝素蛋白微纳米颗粒缓释制剂及制备方法
WO2013022969A1 (en) Docetaxel formulations with lipoic acid
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
US20030082229A1 (en) Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
CN1723887A (zh) 一种紫杉醇注射剂及其制备方法
KR102401546B1 (ko) 탁산, 이의 약학적으로 허용되는 염, 또는 그의 수화물을 함유하는 안정성이 향상된 신규 약제학적 제형
WO2002036582A1 (en) Stable pharmaceutical form of an anticancer drug
HK1021704A (en) Parenteral paclitaxel in a stable non-toxic formulation
CZ2005796A3 (cs) Farmaceutická kompozice obsahující derivát taxanuse zlepsenou terapeutickou úcinností
CN102038636A (zh) 一种含有螯合剂的紫杉烷类药物溶液及其制备方法
HK40033919B (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK1060733B (en) Method for the production of a stable pharmaceutical form of paclitaxel
MXPA97002473A (en) Parenteral pharmaceutical compositions containing gf1209

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)